Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Gains from Investment Securities (2022 - 2025)

Envoy Medical's Gains from Investment Securities history spans 4 years, with the latest figure at -$64000.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 103.09% year-over-year to -$64000.0; the TTM value through Sep 2025 reached -$522000.0, down 125.2%, while the annual FY2024 figure was $2.2 million, 6.22% up from the prior year.
  • Gains from Investment Securities for Q3 2025 was -$64000.0 at Envoy Medical, down from -$37000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.2 million in Q4 2024 and bottomed at -$14.4 million in Q1 2022.
  • The 4-year median for Gains from Investment Securities is -$64000.0 (2022), against an average of -$1.1 million.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 1971.43% in 2024 before it tumbled 260.69% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at -$64000.0 in 2022, then tumbled by 217.19% to -$203000.0 in 2023, then surged by 1191.02% to $2.2 million in 2024, then crashed by 102.89% to -$64000.0 in 2025.
  • Per Business Quant, the three most recent readings for COCH's Gains from Investment Securities are -$64000.0 (Q3 2025), -$37000.0 (Q2 2025), and -$421000.0 (Q1 2025).